



Estudi de la biodisponibilitat del *trans-resveratrol* i el seu efecte quimiopreventiu del càncer de còlon induït per 1,2-dimetilhidrazina en rata

Irene Alfaras Cardenal

ADVERTIMENT. La consulta d'aquesta tesi queda condicionada a l'acceptació de les següents condicions d'ús: La difusió d'aquesta tesi per mitjà del servei TDX (www.tdx.cat) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d'investigació i docència. No s'autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d'un lloc aliè al servei TDX. No s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora.

ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR (framing). Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la persona autora.

WARNING. On having consulted this thesis you're accepting the following use conditions: Spreading this thesis by the TDX (www.tdx.cat) service has been authorized by the titular of the intellectual property rights only for private uses placed in investigation and teaching activities. Reproduction with lucrative aims is not authorized neither its spreading and availability from a site foreign to the TDX service. Introducing its content in a window or frame foreign to the TDX service is not authorized (framing). This rights affect to the presentation summary of the thesis as well as to its contents. In the using or citation of parts of the thesis it's obliged to indicate the name of the author.

VI. BIBLIOGRAFIA

- Abd El-Mohsen, M., Bayele, H., Kuhnle, G., Gibson, G., Debnam, E., Kaila Srari, S., *et al.* Distribution of [³H]*trans*-resveratrol in rat tissues following oral administration. *Br. J. Nutr.* 96 (1), 62-70, 2006.
- Adachi, Y., Suzuki, H., Schinkel, A.H., Sugiyama, Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. *Mol. Pharmacol.* 67 (3), 923-928, 2005.
- Adesanya, S.A., Ogundana, S.K., Roberts, M.F. Dihydrostilbene phytoalexins from *Dioscorea bulbifera* and *D. dumentorum*. *Phytochemistry.* 28 (3), 773-774, 1989.
- Afaq, F., Adhami, V.M., Ahmad, N. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. *Toxicol. Appl. Pharmacol.* 186 (1), 28-37, 2003.
- Aggarwal, B.B., Bhardwaj, A., Aggarwal, R.S., Seeram, N.P., Shishodia, S., Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. *Anticancer Res.* 24 (5A), 2783-2840, 2004.
- Alfaras, I., Juan, M.E., Planas, J.M. *trans*-Resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats. *J. Agric. Food Chem.* 58 (13), 8104-8110, 2010.
- Alfaras, I., Pérez, M., Juan, M.E., Merino, G., Prieto, J.G., Planas, J.M., *et al.* Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of *trans*-resveratrol in knockout mice. *J. Agric. Food Chem.* 58 (7), 4523-4528, 2010.
- Annese, V., Valvano, M.R., Palmieri, O., Latiano, A., Bossa, F., Andriulli, A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. *World J. Gastroenterol.* 12 (23), 3636-3644, 2006.
- Arichi, H., Kimura, Y., Okuda, H., Bada, K., Kozawa, M., Arichi, S. Effects of stilbene components of the roots of *Polygonum cuspidatum* Sieb. Et Zucc. on lipid metabolism. *Chem. Pharm. Bull. (Tokyo).* 30 (5), 1766-1771, 1982.
- Athar, M., Back, J.H., Kopelovich, L., Bickers, D.R., Kim, A.L. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. *Arch. Biochem. Biophys.* 486 (2), 95-102, 2009.
- Aziz, M., Kumar, R., Ahmad, N. Cancer chemopreventive by resveratrol: *in vitro* and *in vivo* studies and the underlying mechanisms (Review). *Int. J. Oncol.* 23 (1), 17-28, 2003.

Balimane, P.V., Han, Y.H., Chong, S. Current industrial practices of assessing permeability and P-glycoprotein interaction. *AAPS J.* 8 (1), E1-E13, 2006.

Banarjee, A., Johnston, J.S., Swaan, P.W. Carrier-mediated mechanisms for cellular drug transport. A: Lu, D.R., Øie, S., editors. *Cellular Drug Delivery: Principles and Practice*. New Jersey: Humana Press; 2004. p. 107-128.

Bass, T.M., Weinkove, D., Houthoofd, K., Gems, D., Partridge, L. Effects of resveratrol on lifespan in *Drosophila melanogaster* and *Caenorhabditis elegans*. *Mech. Ageing. Dev.* 128 (10), 546-552, 2007.

Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., *et al.* Resveratrol improves health and survival of mice on a high-calorie diet. *Nature.* 444 (7117), 337-342, 2006.

Baur, J.M. Resveratrol, sirtuins, and the promise of a DR mimetic. *Mech. Ageing Dev.* 131 (4), 261-269, 2010.

Baur, J.A., Sinclair, D.A. Therapeutic potential of resveratrol: the in vivo evidence. *Nat Rev Drug Discov.* 5 (6), 493-506, 2006.

Belguendouz, L., Fremont, L., Linard, A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. *Biochem. Pharmacol.* 53 (9), 1347-1355, 1997.

Benedetti, M.S., Whomsley, R., Poggesi, I., Cawello, W., Mathy, F.X., Delporte, M.L., *et al.* Drug metabolism and pharmacokinetics. *Drug Metab. Rev.* 41 (3), 344-390, 2009.

Bertelli, A.A., Das, D.K. Grapes, wines, resveratrol, and heart health. *J. Cardiovasc. Pharmacol.* 54 (6), 468-476, 2009.

Bertelli, A.A., Gozzini, A., Stradi, R., Stella, S., Bertelli, A. Stability of resveratrol over time and in the various stages of grape transformation. *Drugs Exp. Clin. Res.* 24 (4), 207-211, 1998.

Bird, R.P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. *Cancer Lett.* 37 (2), 147-151, 1987.

Bird, R.P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. *Cancer Lett.* 93 (1), 55-71, 1995.

Bisht, K., Wagner, K.H., Bulmer, A.C. Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds. *Toxicology.* 278 (1), 88-100, 2010.

- Boocock, D.J., Patel, K.R., Faust, G.E., Normolle, D.P., Marczylo, T.H., Crowell, J.A., *et al.* Quantitation of *trans*-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 848 (2), 182-187, 2007.
- Brisdelli, F., D'Andrea, G., Bozzi, A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. *Curr. Drug Metab.* 10 (6), 530-546, 2009.
- Caderni, G., Femia, A.P., Giannini, A., Favuzza, A., Luceri, C., Salvadori, M. *et al.* Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. *Cancer Res.* 63 (10), 2388-2392, 2003.
- Caderni, G., Giannini, A., Lancioni, L., Luceri, C., Biggeri, A. i Dolara, P. Characterisation of aberrant crypt foci in carcinogen-treated rats: association with intestinal carcinogenesis. *Br. J. Cancer.* 71 (4), 763-769, 1995.
- Campagna, M., Rivas, C. Antiviral activity of resveratrol. *Biochem. Soc. Trans.* 38 (Pt 1), 50-53, 2010.
- Cano-Cebrián, M.J., Zornoza, T., Granero, L., Polache, A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. *Curr. Drug Deliv.* 2 (1), 9-22, 2005.
- Cao, Z., Li, Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. *Eur. J. Pharmacol.* 489 (1-2), 39-48, 2004.
- Cardile, V., Lombardo, L., Spatafora, C., Tringali, C. Chemo-enzymatic synthesis and cell-growth inhibition activity of resveratrol analogues. *Bioorg. Chem.* 33 (1), 22-33, 2005.
- Casper, R.F., Quesme, M., Rogers, I.M., Shirota, T., Joliret, A., Milqrom, E., Savouret, J.F. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. *Mol. Pharmacol.* 56 (4), 784-790, 1999.
- Chan, L.M., Lowes, S., Hirst, B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. *Eur. J. Pharm. Sci.* 21 (1), 25-51, 2004.
- Chong, J., Poutaraud, A., Huguency, P. Metabolism and roles of stilbenes in plants. *Plant Sci.* 177 (3), 143-155, 2009.
- Ciolino, H.P., Daschner, P.J., Yeh, G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. *Cancer Res.* 58 (24), 5707-5712, 1998.

Collett, A., Higgs, N.B., Gironella, M., Zeef, L.A., Hayes, A., Salmo, E., *et al.* Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in *mdr1a(-/-)* mice. *Inflamm. Bowel Dis.* 14 (5), 620-631, 2008.

Collins, A.R. Antioxidant intervention as a route to cancer prevention. *Eur. J. Cancer.* 41 (13), 1923-1930, 2005.

Colom, H., Alfaras, I., Maijó, M., Juan, M.E., Planas, J.M. Population Pharmacokinetic Modeling of *trans*-Resveratrol and Its Glucuronide and Sulfate Conjugates After Oral and Intravenous Administration in Rats. *Pharm. Res.* 28 (7), 1606-1621, 2011.

Corpet, D.E., Pierre, F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. *Eur. J. Cancer.* 41 (13), 1911-1922, 2005.

Cottart, C.H., Nivet-Antoine, V., Laguillier-Morizot, C., Beaudoux, J.L. Resveratrol bioavailability and toxicity in humans. *Mol. Nutr. Food Res.* 54 (1), 7-16, 2010.

Crowell, J.A., Korytko, P.J., Morrissey, R.L., Booth, T.D., Levine, B.S. Resveratrol-associated renal toxicity. *Toxicol. Sci.* 82 (2), 614-619, 2004.

Csiszar, A., Labinskyy, N., Pinto, J.T., Ballabh, P., Zhang, H., Losonczy, G., *et al.* Resveratrol induces mitochondrial biogenesis in endothelial cells. *Am. J. Physiol. Heart Circ. Physiol.* 297 (1), H13-H20, 2009.

Cui, X., Jin, Y., Hofseth, A.B., Pena, E., Habiger, J., Chumanevich, A., *et al.* Resveratrol suppresses colitis and colon cancer associated with colitis. *Cancer Prev. Res. (Phila.)*. 3 (4), 549-559, 2010.

Cummings, J.H., Bingham, S.A. Diet and the prevention of cancer. *BMJ.* 317 (7173), 1636-1640, 1998.

Dal-Pan, A., Blanc, S., Aujard, F. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. *BMC Physiol.* 10, 11, 2010.

Das, D.K., Maulik, N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. *Mol. Interv.* 6 (1), 36-47, 2006.

Dawson, R.J., Locher, K.P. Structure of a bacterial multidrug ABC transporter. *Nature.* 443 (7108), 180-185, 2006.

Dean, M. ABC transporters, drug resistance, and cancer stem cells. *J. Mammary Gland Biol. Neoplasia.* 14 (1), 3-9, 2009.

- Dean, M., Annilo, T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. *Annu. Rev. Genomics Hum. Genet.* 6, 123-142, 2005.
- D'Haens, G.R. Top-down therapy for IBD: rationale and requisite evidence. *Nat. Rev. Gastroenterol. Hepatol.* 7 (2), 86-92, 2010.
- Diplock, A.T., Agget, P.J., Ashwell, M., Bornet, F., Fern, E.B., Roberfroid, M.B. Scientific concepts of functional foods in Europe: Consensus Document. *Brit. J. Nutr.* 81 (4), S1-S27, 1999.
- Docherty, J.J., Fu, M.M., Stiffer, B.S., Limpero, R.J., Pokabla, C.M. DeLucia, A.L. Resveratrol inhibition of herpes simplex virus replication. *Antiviral Res.* 43 (3), 145-155, 1999.
- Druckrey, H., Preussmann, R., Matzkies, F., Ivankovic, S. Selective production of intestinal cancer in rats by 1,2-dimethylhydrazine. *Naturwissenschaften.* 54 (11), 285-286, 1967.
- E**I-Feraly, F. Isolation, characterization, and synthesis of 3,5,4'-trihydroxybibenzyl from *Cannabis sativa*. *J. Nat. Prod.* 47 (1), 89-92, 1984.
- Enokizono, J., Kusuhara, H., Sugiyama, Y. Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases. *Drug Metab. Dispos.* 35 (6), 922-928, 2007.
- F**an, P., Marston, A., Hay, A.E., Hostettmann, K. Rapid separation of three glucosylated resveratrol analogues from the invasive plant *Polygonum cuspidatum* by high-speed countercurrent chromatography. *J. Sep. Sci.* 32 (17), 2979-2984, 2009.
- Femia, A.P., Bendinelli, B., Giannini, A., Salvadori, M., Pinzani, P., Dolara, P., *et al.* Mucin-depleted foci have beta-catenin gene mutations, altered expression of its protein, and are dose- and time-dependent in the colon of 1,2-dimethylhydrazine-treated rats. *Int. J. Cancer.* 116 (1), 9-15, 2005.
- Femia, A.P., Dolara, P., Caderni, G. Mucin-depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are useful biomarkers for colon carcinogenesis. *Carcinogenesis.* 25 (2), 277-281, 2004.
- Femia, A.P., Dolara, P., Giannini, A., Salvadori, M., Biggeri, A., Caderni, G. Frequent mutation of Apc gene in rat colon tumors and mucin-depleted foci, preneoplastic lesions in experimental colon carcinogenesis. *Cancer Res.* 67 (2), 445-449, 2007.
- Ferlay, J., Parkin, D.M., Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. *Eur. J. Cancer.* 46 (4), 765-781, 2010.

Fiala, E. Investigations into the metabolism and mode of action of the colon carcinogen 1, 2-dimethylhydrazine. *Cancer*. 36 (6 Suppl), 2407-2412, 1975.

Filipe, M.I. Mucous secretion in rat colonic mucosa during carcinogenesis induced by dimethylhydrazine. A morphological and histochemical study. *Br. J. Cancer*. 32 (1), 60-77, 1975.

Fischer-Posovszky, P., Kukulus, V., Tews, D., Unterkircher, T., Debatin, K.M., Fulda, S., *et al.* Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. *Am. J. Clin. Nutr.* 92 (1), 5-15, 2010.

Flores-Sanchez, I.J., Verpoorte, R. Secondary metabolism in cannabis. *Phytochem. Rev.* 7 (3), 615-639, 2008.

Fodde, R., Kuipers, J., Rosenberg, C., Smits, R., Kielman, M., Gaspar, C., *et al.* Mutations in the APC tumour suppressor gene cause chromosomal instability. *Nat. Cell Biol.* 3 (4), 433-438, 2001.

Frankel, E.N., Waterhouse, A.L., Kinsella, J.E. Inhibition of human LDL oxidation by resveratrol. *Lancet*. 341 (8852), 1103-1104, 1993.

Frémont, L., Belguendouz, L., Delpal, S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. *Life. Sci.* 64 (26), 2511-2521, 1999.

Fritzemeier, K.H., Kindl, H. 9,10-Dihydrophenanthrenes as phytoalexins of Orchidaceae. *Eur. J. Biochem.* 133 (3), 545- 550, 1983.

Fromm, M.F. Importance of P-glycoprotein at blood–tissue barriers. *Trends Pharmacol. Sci.* 25 (8), 423-429, 2004.

Fu, Z.D., Cao, Y., Wang, K.F., Xu, S.F., Han, R. Chemopreventive effect of resveratrol to cancer. *Ai Zheng.*, 23 (8), 869-873, 2004.

Fulda, S., Debatin, K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand induced apoptosis by the chemopreventive agent resveratrol. *Cancer Res.*, 64 (1), 337-346, 2004.

Gakh, A.A., Anisimova, N.Y., Kiselevsky, M.V., Sadovnikov, S.V., Stankov, I.N., Yudin, M.V., *et al.* Dihydro-resveratrol--a potent dietary polyphenol. *Bioorg. Med. Chem. Lett.* 20 (20), 6149-6151, 2010.

Garvin, S., Ollinger, K., Dabrosin, C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. *Cancer Lett.*, 231 (1), 113-122, 2006.

- Gautam, R., Jachak, S.M. Recent developments in anti-inflammatory natural products. *Med. Res. Rev.* 29 (5), 767-820, 2009.
- Gehm, B.D., McAndrews, J.M., Chien, P.Y., Jameson, J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. *Proc. Natl. Acada. Sci., USA*, 94 (25), 14138-14143, 1997.
- Glauert, H.P., Bennink, M.R. Metabolism of 1,2-dimethylhydrazine by cultured rat colon epithelial cells. *Nutr. Cancer.* 5 (2), 78-86, 1983.
- González-Pons, E. Estudi del metabolisme intestinal i l'activitat sobre el sistema reproductor masculí del *trans*-resveratrol, un antioxidant natural del raïm. Tesi doctoral, 2005.
- Gorham, J. The biochemistry of the stilbenoids. 1^a ed. Regne Unit: Chapman & Hall; 1995.
- Gromadzińska, J., Wasowicz, W. The role of reactive oxygen species in the development of malignancies. *Int. J. Occup. Med. Environ. Health.* 13 (3), 233-245, 2000.
- Grønbaek, M. Wine and mortality. Evidence for causal inference? *Dan. Med. Bull.* 47 (4), 271-282, 2000.
- Gusman, J., Malonne, H., Atassi, G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. *Carcinogenesis*, 22 (8), 1111-1117, 2001.
- H**all, M.D., Handley, M.D., Gottesman, M.M. Is resistance useless? Multidrug resistance and collateral sensitivity. *Trends Pharmacol. Sci.* 30 (10), 546-556, 2009.
- Halls, C., Yu, O. Potential for metabolic engineering of resveratrol biosynthesis. *Trends Biotechnol.* 26 (2), 77-81, 2008.
- Hambly, R.J., Rumney, C.J., Cunninghame, M., Fletcher, J.M., Rijken, P.J., Rowland, I.R. Influence of diets containing high and low risk factors for colon cancer on early stages of carcinogenesis in human flora-associated (HFA) rats. *Carcinogenesis*. 18 (8), 1535-1539, 1997.
- Harikumar, K.B., Aggarwal, B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. *Cell Cycle.* 7 (8), 1020-1035, 2008.
- He, H., Lyons, K.A., Shen, X., Yao, Z., Bleasby, K., Chan, G., *et al.* Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure. *Xenobiotica.* 39 (9), 687-693, 2009.

Hebbar, V., Shen, G., Hu, R., Kim, B.R., Chen, C., Korytko, P.J., *et al.* Toxicogenomics of resveratrol in rat liver. *Life Sci.* 76 (20), 2299-2314, 2005.

Henry, C., Vitrac, X., Decendit, A., Ennamany, R., Krisa, S., Mérillon, J.M. Cellular uptake and efflux of *trans*-piceid and its aglycone *trans*-resveratrol on the apical membrane of human intestinal Caco-2 cells. *J. Agric. Food Chem.* 53 (3), 798-803, 2005.

Hernández-Romero, Y., Rojas, J.I., Castillo, R., Rojas, A., Mata, R. Spasmolytic effects, mode of action, and structure-activity relationships of stilbenoids from *Nidema boothii*. *J. Nat. Prod.* 67 (2), 160-167, 2004.

Hernández-Romero, Y., Acevedo, L., Sánchez, M. de L., Shier, W.T., Abbas, H.K., Mata, R. Phytotoxic activity of bibenzyl derivatives from the orchid *Epidendrum rigidum*. *J. Agric. Food Chem.* 53 (16), 6276-6280, 2005.

Herron, D.C., Shank, R.C. DNA methylation during chronic administration of 1,2-dimethylhydrazine in a carcinogenic regimen. *Carcinogenesis.* 3 (8), 857-860, 1982.

Hines, R.N., McCarver, D.G. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. *J. Pharmacol. Exp. Ther.* 300 (2), 355-360, 2002.

Ho, G.T., Moodie, F.M., Satsangi, J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? *Gut.* 52 (5), 759-766, 2003.

Howitz, T.K., Bitterman, J.K., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, G.J., *et al.* Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature*, 425 (6954), 191-196, 2003.

Hung, C.W., Chen, Y.C., Hsieh, W.L., Chiou, S.H., Kao, C.L. Ageing and neurodegenerative diseases. *Ageing Res. Rev.* 9 (Suppl 1), S36-S46, 2010.

Huls, M., Russel, F.G., Masereeuw, R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. *J. Pharmacol. Exp. Ther.* 328 (1), 3-9, 2009.

Jackson, P.E., Cooper, D.P., O'Connor, P.J., Povey, A.C. The relationship between 1,2-dimethylhydrazine dose and the induction of colon tumours: tumour development in female SWR mice does not require a K-ras mutational event. *Carcinogenesis.* 20 (3), 509-513, 1999.

Jang, M.S., Cai, E.N., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, D.W.W., *et al.* Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. *Science*, 275 (5297), 218-220, 1997.

Jenab, M., Chen, J., Thompson, L.U. Sialomucin production in aberrant crypt foci relates to degree of dysplasia and rate of cell proliferation. *Cancer Lett.* 165 (1), 19-25, 2001.

- Jiang, H., Wood, K.V., Morgan, J.A. Metabolic engineering of the phenylpropanoid pathway in *Saccharomyces cerevisiae*. *Appl. Environ. Microbiol.* 71 (6), 2962-2969, 2005.
- Juan, M.E., Alfara, I., Planas, J.M. Determination of dihydroresveratrol in rat plasma by HPLC. *J. Agric. Food Chem.* 58 (12), 7472-7475, 2010.
- Juan, M.E., Buenafuente, J., Casals, I., Planas, J.M. Plasmatic levels of *trans*-resveratrol in rats. *Food Res. Int.* 35 (2-3), 195-199, 2002a.
- Juan, M.E., González-Pons, E., Munuera, T., Ballester, J., Rodríguez-Gil, J.E., Planas, J.M. *trans*-Resveratrol, a natural antioxidant from grapes, increases sperm output in healthy rats. *J. Nutr.* 135 (4), 757-760, 2005.
- Juan, M.E., González-Pons, E., Planas, J.M. Multidrug resistance proteins restrain the intestinal absorption of *trans*-resveratrol in rats. *J. Nutr.* 140 (3), 489-495, 2010a.
- Juan, M.E., Maijó, M., Planas, J.M. Quantification of *trans*-resveratrol and its metabolites in rat plasma and tissues by HPLC. *J. Pharm. Biomed. Anal.* 51 (2), 391-398, 2010b.
- Juan, M.E., Vinardell, M.P., Planas, J.M. The daily oral administration of high doses of *trans*-resveratrol to rats for 28 days is not harmful. *J. Nutr.* 132 (2), 257-260, 2002b.
- Juan, M.E., Wenzel, U., Daniel, H., Planas, J.M. Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. *J. Agric. Food Chem.* 56 (12), 4813-4818, 2008.
- Jung, C.M., Heinze, T.M., Schnackenberg, L.K., Mullis, L.B., Elkins, S.A., Elkins, C.A., *et al.* Interaction of dietary resveratrol with animal-associated bacteria. *FEMS Microbiol. Lett.* 297 (2), 266-273, 2009.
- K**ageura, T., Matsuda, H., Morikawa, T., Toguchida, I., Harima, S., Oda, M., *et al.* Inhibitors from rhubarb on lipopolysaccharide-induced nitric oxide production in macrophages: structural requirements of stilbenes for the activity. *Bioorg. Med. Chem.* 9 (7), 1887-1893, 2001.
- Kang, O.H., Jang, H.J., Chae, H.S., Oh, Y.C., Choi, J.G., Lee, Y.S., *et al.* Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. *Pharmacol. Res.* 59 (5), 330-337, 2009.
- Kannan, P., John, C., Zoghbi, S.S., Halldin, C., Gottesman, M.M., Innis, R.B., *et al.* Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. *Clin. Pharmacol. Ther.* 86 (4), 368-377, 2009.
- Kelly, G. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. *Altern. Med. Rev.* 15 (3), 245-263, 2010.

Kensler, T., Guyton, K., Egner, P., McCarthy, T., Lesko, S., Akman, S. Role of reactive intermediates in tumor promotion and progression. *Prog. Clin. Biol. Res.* 391, 103-116, 1995.

Khanduja, K.L., Bhardwaj, A. i Kaushik, G. Resveratrol inhibits N-nitrosodiethylamine-induced ornithine decarboxylase and cyclooxygenase in mice. *J. Nutr. Sci. Vitaminol. (Tokyo)*. 50 (1), 61-65, 2004.

Kimura, Y., Okuda, H. Resveratrol isolated from *Polygonum cuspidatum* root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. *J. Nutr.* 131 (6), 1844-1849, 2001.

Kinzler, K.W., Vogelstein, B. Lessons from hereditary colorectal cancer. *Cell.* 87 (2), 159-170, 1996.

Klaassen, C.D., Aleksunes, L.M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. *Pharmacol. Rev.* 62 (1), 1-96, 2010.

Koboziev, I., Karlsson, F., Grisham, M.B. Gut-associated lymphoid tissue, T cell trafficking, and chronic intestinal inflammation. *Ann. N. Y. Acad. Sci.* 1207 (Suppl 1), E86-E93, 2010.

Kodan, A., Kuroda, H., Sakai, F. A stilbene synthase from Japanese red pine (*Pinus densiflora*): implications for phytoalexin accumulation and down-regulation of flavonoid biosynthesis. *Proc. Natl. Acad. Sci. U.S.A.* 99 (5), 3335-3339, 2002.

Kong, H., Kim, Y., Lee, Y., Choi, B. Sulfate-conjugated methylprednisolone: Evaluation as a colon-specific methylprednisolone prodrug and comparison with sulfate-conjugated prednisolone and dexamethasone. *J. Drug Target.* 17 (2), 159-167, 2009.

Lampe, J.W., Chang, J.L. Interindividual differences in phytochemical metabolism and disposition. *Semin. Cancer Biol.* 17 (5), 347-353, 2007.

Larrosa, M., Yañez-Gascón, M.J., Selma, M.V., González-Sarrías, A., Toti, S., Cerón, J.J., *et al.* Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. *J. Agric. Food Chem.* 57 (6), 2211-2220, 2009.

de la Lastra, C.A., Villegas, I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. *Mol. Nutr. Food Res.* 49 (5), 405-430, 2005.

Levsen, K., Schiebel, H.M., Behnke, B., Dötzer, R., Dreher, W., Elend, M., *et al.* Structure elucidation of phase II metabolites by tandem mass spectrometry: an overview. *J. Chromatogr. A.* 1067 (1-2), 55-72, 2005.

Li, Z.G., Hong, T., Shimada, Y., Komoto, I., Kawabe, A., Ding, Y. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. *Carcinogenesis*. 23 (9), 1531-1536, 2002.

Lin, K.H., Hsiao, G., Shih, C.M., Chou, D.S., Sheu, J.R. Mechanisms of resveratrol-induced platelet apoptosis. *Cardiovasc Res*. 83 (3), 575-585, 2009.

Locher, K.P. Review. Structure and mechanism of ATP-binding cassette transporters. *Phil. Trans. R. Soc. B*. 364 (1514), 239-245, 2009.

Maier-Salamon, A., Böhmendorfer, M., Reznicek, G., Thalhammer, T., Szekeres, T., Jaeger, W. Hepatic Glucuronidation of Resveratrol: Interspecies Comparison of Enzyme Kinetic Profiles in Human, Mouse, Rat and Dog. *Drug Metab. Pharmacokinet*. 2011. doi:10.2133/dmpk.DMPK-11-RG-006.

Maier-Salamon, A., Hagenauer, B., Reznicek, G., Szekeres, T., Thalhammer, T., Jäger, W. Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. *J. Pharm. Sci*. 97 (4), 1615-1628, 2008.

Maier-Salamon, A., Hagenauer, B., Wirth, M., Gabor, F., Szekeres, T., Jäger, W. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. *Pharm. Res*. 23 (9), 2107-2115, 2006.

Marier, J.F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.P., Ducharme, M.P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. *J. Pharmacol. Exp. Ther*. 302 (1), 369-373, 2002.

Martín, A.R., Villegas, I., Sánchez-Hidalgo, M., de la Lastra, C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. *Br. J. Pharmacol*. 147 (8), 873-885, 2006.

Martinez, M. E., O'Brien, T.G., Fultz, K.E., Babbar, N., Yerushalmi, H., Qu, N., *et al*. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. *Proc. Natl Acad. Sci. USA*. 100 (13), 7859-7864, 2003.

Maskens, A.F. Confirmation of the two-step nature of chemical carcinogenesis in the rat colon adenocarcinoma model. *Cancer Res*. 41 (3), 1240-1245, 1981.

McConnell, E.L., Fadda, H.M., Basit, A.W. Gut instincts: explorations in intestinal physiology and drug delivery. *Int. J. Pharm*. 364 (2), 213-226, 2008.

McLellan, E.A., Medline, A., Bird, R.P. Sequential analysis of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. *Cancer Res.* 51 (19), 5270-5274, 1991.

Miller, R.A., Harrison, D.E., Astle, C.M., Baur, J.A., Boyd, A.R., de Cabo, R., *et al.* Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. *J. Gerontol. A Biol. Sci. Med. Sci.* 66 (2), 191-201, 2011.

Muntané, J. Regulation of drug metabolism and transporters. *Curr. Drug Metab.* 10 (8), 932-945, 2009.

Murakami, T., Takano, M. Intestinal efflux transporters and drug absorption. *Expert Opin. Drug Metab. Toxicol.* 4 (7), 923-939, 2008.

Nakagama, H., Nakanishi, M., Ochiai, M. Modeling human colon cancer in rodents using a food-borne carcinogen, PhIP. *Cancer Sci.* 96 (10), 627-636, 2005.

Nakamura, T., Yamamori, M., Sakaeda, T. Pharmacogenetics of intestinal absorption. *Curr. Drug Deliv.* 5 (3), 153-169, 2008.

Namasivayam, N. Chemoprevention in experimental animals. *Ann. N. Y. Acad. Sci.* 1215, 60-71, 2011.

Narayan, S., Roy, D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. *Mol. Cancer.* 2, 41, 2003.

Ohnishi, N., Yokoyama, T. Interactions between medicines and functional foods or dietary supplements. *Keio J. Med.* 53 (3), 137-150, 2004.

Orsini, F., Verotta, L., Lecchi, M., Restano, R., Curia, G., Redaelli, E., *et al.* Resveratrol derivatives and their role as potassium channels modulators. *J. Nat. Prod.* 67 (3), 421-426, 2004.

Ortuño, J., Covas, M.I., Farre, M., Pujadas, M., Fito, M., Khymenets, O., *et al.* Matrix effects on the bioavailability of resveratrol in humans. *Food Chem.* 120 (4), 1123-1130, 2010.

Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., *et al.* Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell.* 87 (5), 803-809, 1996.

Pacholec, M., Bleasdale, J.E., Chrnyk, B., Cunningham, D., Flynn, D., Garofalo, R.S., *et al.* SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. *J. Biol. Chem.* 285 (11), 8340-8351, 2010.

Pallàs, M., Casadesús, G., Smith, M.A., Coto-Montes, A., Pelegri, C., Vilaplana, J., *et al.* Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. *Curr. Neurovasc. Res.* 6 (1), 70-81, 2009.

Pang, K.S., Maeng, H.J., Fan, J. Interplay of transporters and enzymes in drug and metabolite processing. *Mol. Pharm.* 6 (6), 1734-1755, 2009.

Panwala, C.M., Jones, J.C., Viney, J.L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, *mdr1a*, spontaneously develop colitis. *J. Immunol.* 161 (10), 5733-5744, 1998.

Patel, K.R., Brown, V.A., Jones, D.J., Britton, R.G., Hemingway, D., Miller, A.S., *et al.* Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. *Cancer Res.* 70 (19), 7392-7399, 2010.

Paul, B., Masih, I., Deopujari, J., Charpentier, C. Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. *J. Ethnopharmacol.* 68 (1-3), 71-76, 1999.

Pedras, M.S., Ahiahonu, P.W. Metabolism and detoxification of phytoalexins and analogs by phytopathogenic fungi. *Phytochemistry.* 66 (4), 391-411, 2005.

Penumathsa, S.V., Maulik, N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. *Can. J. Physiol. Pharmacol.* 87 (4), 275-286, 2009.

Pervaiz, S., Holme, A.L. Resveratrol: its biologic targets and functional activity. *Antioxid. Redox Signal.* 11 (11), 2851-2897, 2009.

Pierre, F., Freeman, A., Taché, S., Van der Meer, R., Corpet, D.E. Beef meat and blood sausage promote the formation of azoxymethane-induced mucin-depleted foci and aberrant crypt foci in rat colons. *J. Nutr.* 134 (10), 2711-2716, 2004.

Pretlow, T.P., Barrow, B.J., Ashton, W.S., O'Riordan, M.A., Pretlow, T.G., Jurcisek, J.A., *et al.* Aberrant crypts: putative preneoplastic foci in human colonic mucosa. *Cancer Res.* 51 (5), 1564-1567, 1991.

Procko, E., O'Mara, M.L., Bennett, W.F., Tieleman, D.P., Gaudet, R. The mechanism of ABC transporters: general lessons from structural and functional studies of an antigenic peptide transporter. *FASEB J.* 23 (5), 1287-1302, 2009.

Raju, J., Bird, R.P. Energy restriction reduces the number of advanced aberrant crypt foci and attenuates the expression of colonic transforming growth factor β and

cyclooxygenase isoforms in Zucker obese (fa/fa) rats. *Cancer Res.* 63 (20), 6595-6601, 2003.

Rao, C.V., Wang, C., Simi, B., Lubet, R.A., Kelloff, G.J., Steele, V., *et al.* Enhancement of experimental colon cancer by genistein. *Cancer Res.* 57 (17), 3717-3722, 1997.

Reagan-Shaw, S., Afaq, F., Aziz, M.H., Ahmad, N. Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. *Oncogene*, 23 (30), 5151-5160, 2004.

Reddy, B.S. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. *Environ. Mol. Mutagen.* 44 (1), 26-35, 2004.

Renaud, S., de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. *Lancet.* 339 (8808), 1523-1526, 1992.

Renaud, S.C., Guéguen, R., Siest, G., Salamon, R. Wine, beer, and mortality in middle-aged men from eastern France. *Arch. Intern. Med.* 159 (16), 1865-1870, 1999.

Resta-Lenert, S., Smitham, J., Barrett, K.E. Epithelial dysfunction associated with the development of colitis in conventionally housed *mdr1a*^{-/-} mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* 289 (1), G153-G162, 2005.

Revel, A., Haimov-Kochman, R., Porat, A., Lewin, A., Simon, A., Laufer, N., *et al.* In vitro fertilization-intracytoplasmic sperm injection success rates with cryopreserved sperm from patients with malignant disease. *Fertil. Steril.* 84 (1), 118-122, 2005.

Roberfroid, M.B. Global view on functional foods: European perspectives. *Br. J. Nutr.* 88 (Suppl 2), S133-138, 2002.

Roberts, D.M., Buckley, N.A. Pharmacokinetic considerations in clinical toxicology: clinical applications. *Clin. Pharmacokinet.* 46 (11), 897-939, 2007.

Robey, R.W., To, K.K., Polgar, O., Dohse, M., Fetsch, P., Dean, M., *et al.* ABCG2: a perspective. *Adv. Drug Deliv. Rev.* 61 (1), 3-13, 2009.

Rodrigues, M.A.M., Silva, L.A.G., Salvadori, D.M.F., de Camargo, J.L.V. i Montenegro, M.R. Aberrant crypt foci and colon cancer: comparison between a short- and medium-term bioassay for colon carcinogenesis using dimethylhydrazine in Wistar rats. *Braz. J. Med. Biol. Res.* 35 (3), 251-355, 2002.

Sabolovic, N., Humbert, A.C., Radomska-Pandya, A., Magdalou, J. Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. *Biopharm. Drug Dispos.* 27 (4), 181-189, 2006.

- Sakamoto, H., Yokota, H., Kibe, R., Sayama, Y., Yuasa, A. Excretion of bisphenol A-glucuronide into the small intestine and deconjugation in the cecum of the rat. *Biochim. Biophys. Acta.* 1573 (2), 171-176, 2002.
- Sale, S., Verschoyle, R.D., Boocock, D., Jones, D.J., Wilsher, N., Ruparelia, K.C., *et al.* Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. *Br. J. Cancer.* 90 (3), 736-744, 2004.
- Sánchez-Fidalgo, S., Cárdeno, A., Villegas, I., Talero, E., de la Lastra, C.A. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. *Eur. J. Pharmacol.* 633 (1-3), 78-84, 2010.
- Schinkel, A.H., Mol, C.A., Wagenaar, E., van Deemter, L., Smit, J.J., Borst, P. Multidrug resistance and the role of P-glycoprotein knockout mice. *Eur. J. Cancer.* 31A (7-8), 1295-1298, 1995.
- Sengottuvelan, M., Viswanathan, P., Nalini, N. Chemopreventive effect of *trans*-resveratrol--a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. *Carcinogenesis.* 27 (5), 1038-1046, 2006.
- Sergent, T., Ribonnet, L., Kolosova, A., Garsou, S., Schaut, A., De Saeger, S., *et al.* Molecular and cellular effects of food contaminants and secondary plant components and their plausible interactions at the intestinal level. *Food Chem. Toxicol.* 46 (3), 813-841, 2008.
- Shukla, Y., Singh, R. Resveratrol and cellular mechanisms of cancer prevention. *Ann. N. Y. Acad. Sci.* 1215, 1-8, 2011.
- Siemann, E.H., Creasy, L.L. Concentration of the phytoalexin resveratrol in wine. *Am. J. Enol. Vitic.* 43 (1), 41-52, 1992.
- Singh, U.P., Singh, N.P., Singh, B., Hofseth, L.J., Price, R.L., Nagarkatti, M., *et al.* Resveratrol (*trans*-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. *J. Pharmacol. Exp. Ther.* 332 (3), 829-839, 2010.
- Sohn, K.J., Puchyr, M., Salomon, R.N., Graeme-Cook, F., Fung, L., Choi, S.W., *et al.* The effect of dietary folate on Apc and p53 mutations in the dimethylhydrazine rat model of colorectal cancer. *Carcinogenesis.* 20 (12), 2345-2350, 1999.

Soleas, G.J., Diamandis, E.P., Goldberg, D.M. Resveratrol: a molecule whose time has come? And gone? *Clin. Biochem.* 30 (2), 91-113, 1997.

Stanley, L.A., Horsburgh, B.C., Ross, J., Scheer, N., Wolf, C.R. Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior. *Drug Metab. Rev.* 41 (1), 27-65, 2009.

Subbaramaiah, K. Chung, W.J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., *et al.* Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. *J. Biol. Chem.*, 273 (34), 21875-21882, 1998.

Suh, N., Paul, S., Hao, X., Simi, B., Xiao, H., Rimando, A.M., *et al.* Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. *Clin. Cancer Res.* 13 (1), 350-355, 2007.

Sugimura, T., Terada, M., Yokota, J., Hirohashi, S., Wakabayashi, K. Multiple genetic alterations in human carcinogenesis. *Environ. Health Perspect.* 98, 5-12, 1992.

Sun, A.Y., Wang, Q., Simonyi, A., Sun, G.Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. *Mol. Neurobiol.* 41 (2-3), 375-383, 2010.

Szkudelski, T. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. *Am. J. Physiol. Endocrinol. Metab.* 293 (4), E901-E907, 2007.

Tadolini, B., Juliano, C., Piu, L., Franconi, F., Cabrini, L. Resveratrol inhibition of lipid peroxidation. *Free Radic. Res.* 33 (1), 105-114, 2000.

Takahashi, M., Mutoh, M., Kawamori, T., Sugimura, T., Wakabayashi, K. Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. *Carcinogenesis.* 21 (7), 1319-1327, 2000.

Tanaka, Y., Slitt, A.L., Leazer, T.M., Maher, J.M., Klaassen, C.D. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. *Biochem. Biophys. Res. Commun.* 326 (1), 181-187, 2005.

Tessitore, L., Davit, A., Sarotto, I., Caderni, G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. *Carcinogenesis.* 21 (8), 1619-1622, 2000.

Thelen, K., Dressman, J.B. Cytochrome P450-mediated metabolism in the human gut wall. *J. Pharm. Pharmacol.* 61 (5), 541-558, 2009.

Tseng, S.H., Lin, S.M., Chen, J.C., Su, Y.H., Huang, H.Y., Chen, C.K., *et al.* Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. *Clin. Cancer Res.* 10 (6), 2190-2202, 2004.

Uguralp, S., Usta, U., Mizrak, B. Resveratrol may reduce apoptosis of rat testicular germ cells after experimental testicular torsion. *Eur. J. Pediatr. Surg.* 15 (5), 333-336, 2005.

Van de Wetering, K., Burkon, A., Feddema, W., Bot, A., de Jonge, H., Somoza, V., *et al.* Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. *Mol. Pharmacol.* 75 (4), 876-885, 2009.

Van Herwaarden, A.E., Jonker, J.W., Wagenaar, E., Brinkhuis, R.F., Schellens, J.H., Beijnen, J.H., *et al.* The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Cancer Res.* 63 (19), 6447-6452, 2003.

Vastano, B.C., Chen, Y., Zhu, N., Ho, C.T., Zhou, Z., Rosen, R.T. Isolation and identification of stilbenes in two varieties of *Polygonum cuspidatum*. *J. Agric. Food Chem.* 48 (2), 253-256, 2000.

Verghese, M., Rao, D.R., Chawan, C.B., Williams, L.L., Shackelford, L. Dietary inulin suppresses azoxymethane-induced aberrant crypt foci and colon tumours at the promotion stage in young Fisher 344 rats. *J. Nutr.* 132 (9), 2809-2813, 2002.

Vitrac, X., Desmoulière, A., Brouillaud, B., Krisa, S., Deffieux, G., Barthe, N., *et al.* Distribution of [¹⁴C]-*trans*-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. *Life Sci.* 72 (20), 2219-2233, 2003.

Vivona, A.A., Shpitz, B., Medline, A., Bruce, W.R., Hay, K., Ward, M.A., *et al.* K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. *Carcinogenesis.* 14 (9), 1777-1781, 1993.

Vlaming, M.L., Lagas, J.S., Schinkel, A.H. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. *Adv. Drug Deliv. Rev.* 61 (1), 14-25, 2009.

Vrhovsek, U., Wendelin, S., Eder, R. Effects of Various Vinification Techniques on the Concentration of *cis*- and *trans*-Resveratrol and Resveratrol Glucoside Isomers in Wine. *Am. J. Enol. Vitic.* 48 (2), 214-219, 1997.

Walle, T. Bioavailability of resveratrol. *Ann. N. Y. Acad. Sci.* 1215, 9-15, 2011.

Walle, T., Hsieh, F., DeLegge, M.H., Oatis, J.E. Jr., Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. *Drug Metab. Dispos.* 32 (12), 1377-1382, 2004.

Wang, Q., Xu, J., Rottinghaus, G.E., Simonyi, A., Lubahn, D., Sun, G.Y., *et al.* Resveratrol protects against global cerebral ischemic injury in gerbils. *Brain Res.* 958 (2), 439-447, 2002.

Wang, D., Hang, T., Wu, C., Liu, W. Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 829 (1-2), 97-106, 2005.

Wargovich, M.J., Jimenez, A., McKee, K., Steele, V.E., Velasco, M., Woods, J., *et al.* Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. *Carcinogenesis.* 21 (6), 1149-1155, 2000.

Watson, A.J. An overview of apoptosis and the prevention of colorectal cancer. *Crit. Rev. Oncol. Hematol.* 57 (2), 107-121, 2006.

Wells, H.G., Slye, M., Holmes, H.F. Comparative pathology of cancer of the alimentary canal, with report of cases in mice. *Am. J. Cancer.* 33, 223-238, 1938.

Westphal, C.H., Dipp, M.A., Guarente, L. A therapeutic role for sirtuins in diseases of aging? *Trends Biochem. Sci.* 32 (12), 555-560, 2007.

Wilk, J.N., Bilsborough, J., Viney, J.L. The *mdr1a*^{-/-} mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease. *Immunol. Res.* 31 (2), 151-159, 2005.

Williams, D., Verghese, M., Walker, L.T., Boateng, J., Shackelford, L., Chawan, C.B. Flax seed oil and flax seed meal reduce the formation of aberrant crypt foci (ACF) in azoxymethane-induced colon cancer in Fisher 344 male rats. *Food Chem. Toxicol.* 45 (1), 153-159, 2007.

Wulff, H., Castle, N.A., Pardo, L.A. Voltage-gated potassium channels as therapeutic targets. *Nat. Rev. Drug Discov.* 8 (12), 982-1001, 2009.

Xavier, R.J., Podolsky, D.K. Unravelling the pathogenesis of inflammatory bowel disease. *Nature.* 448 (7152), 427-434, 2007.

Xiao, K., Zhang, H.J., Xuan, L.J., Zhang, J., Xu, Y.M., Bai, D.L. Stilbenoids: chemistry and bioactivities. A: Atta-ur-Rahman, F.R.S., editor. *Studies in natural products chemistry.* Regne Unit: Elsevier; 2008. p. 453-646.

Xie, C.F., Yuan, H.Q., Qu, J.B., Xing, J., Lü, B.B., Wang, X.N., *et al.* Biocatalytic production of acyclic bis[bibenzyls] from dihydroresveratrol by crude *Momordica charantia* peroxidase. *Chem. Biodivers.* 6 (8), 1193-1201, 2009.

Xing, Y., Clements, W.K., Kimelman, D., Xu, W. Crystal structure of a beta-catenin/axin complex suggests a mechanism for the beta-catenin destruction complex. *Genes Dev.* 17 (22), 2753-2764, 2003.

Yao, J., Wang, J.Y., Liu, L., Li, Y.X., Xun, A.Y., Zeng, W.S., *et al.* Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. *Arch. Med. Res.* 41 (4), 288-294, 2010.

Yoshimi, N., Morioka, T., Kinjo, T., Inamine, M., Kaneshiro, T., Shimizu, T., *et al.* Histological and immunohistochemical observations of mucin-depleted foci (MDF) stained with alcian blue, in rat colon carcinogenesis induced with 1,2-dimethylhydrazine dihydrochloride. *Cancer Sci.* 95 (10), 792-797, 2004.

Youn, J., Lee, J.S., Na, H.K., Kundu, J.K., Surh, Y.J. Resveratrol and piceatannol inhibit iNOS expression and NF-kappaB activation in dextran sulfate sodium-induced mouse colitis. *Nutr. Cancer.* 61 (6), 847-854, 2009.

Yu, L., Sun, Z.J., Wu, S.L., Pan, C.E. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. *World J. Gastroenterol.* 9 (10), 2341-2343, 2003.

Zamek-Gliszczynski, M.J., Nezasa, K., Tian, X., Kalvass, J.C., Patel, N.J., Raub, T.J., *et al.* The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. *Mol. Pharmacol.* 70 (6), 2127-2133, 2006.

Zheng, Y., Kramer, P.M., Lubet, R.A., Steele, V.E., Kelloff, G.J., Pereira, M.A. Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. *Carcinogenesis.* 20 (2), 255-260, 1999.

Zhou, H.B., Chen, J.J., Wang, W.X., Cai, J.T., Du, Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. *World J. Gastroenterol.*, 11 (2), 280-284, 2005.